FindTrial
Sign In

To Assess the Skin Tone Benefits of the Pearl Tomato in Healthy Adults

A Single-Centre, Randomized Placebo-Controlled Study to Assess the Skin Tone Enhancement Benefits of the Pearl Tomato in Healthy Adults - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072010
Enrollment
40
Registered
2024-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Vesta Nutra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy Indian male and female participants aged 18-50 years. 2. Fitzpatrick Skin Types I-IV. 3. Presence of visible facial dark spots and pigmentation. 4. Healthy face skin free of eczema, wounds, and inflammatory scars. 5. Absence of signs of infectious and evolutive pathology. 6. Willing to comply with study requirements.

Exclusion criteria

Exclusion criteria: 1. Participants with chronic dermatosis or cutaneous hypersensitivity. 2. Clinically significant systemic or cutaneous disease, chronic illness, or recent major surgery. 3. Allergy or sensitivity to specified products or substances. 4. Pregnant or breastfeeding women, or use of hormonal birth control. 5. Recent participation in another clinical trial. 6. Current medication influencing study interpretation. 7. Unwillingness to discontinue other facial products.

Design outcomes

Primary

MeasureTime frame
1) Overall hyperpigmentation, skin tone, tactile smoothness, brightness, and radiance. 2) Improvement in skin brightness and investigator s assessment on skin brightness, tone, smoothness, glow ,radiance, colour. 3) Measurement of skin tone , UV pigmentation, dark spots, pores and wrinkles. 4) Skin colour assessment using Colori Probe. 5) TEWL, Elasticity, and Hydration assessments using DermaLab Probes. 6) Change in tyrosinase biomarker level.Timepoint: Day 0, Day 15, Day 30, Day 60 & Day 90—

Secondary

MeasureTime frame
1. Record any change in vital signs (blood pressure, pulse rate, body temperature). 2. Record any change in CBS parameters, Liver Function Test (LFT), Renal Function Test (RFT) parameters and RBS. 3. Occurrence of the treatment-related adverse events (AEs) during study period. 4. Subjective assessment of treatment satisfaction, and perception regarding changes in skin brightness, whiteness, and pigmentation.Timepoint: Day 0, Day 15, Day 30, Day 60 & Day 90—

Countries

India

Contacts

Public ContactMeena Dalal

TrialGuna Private Limited

drsohanshetty@yahoo.co.in08867125414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026